TWST vs. DNLI, VCEL, KYMR, CGON, APGE, ACLX, SANA, RXRX, DNA, and IMCR
Should you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Denali Therapeutics (DNLI), Vericel (VCEL), Kymera Therapeutics (KYMR), CG Oncology (CGON), Apogee Therapeutics (APGE), Arcellx (ACLX), Sana Biotechnology (SANA), Recursion Pharmaceuticals (RXRX), Ginkgo Bioworks (DNA), and Immunocore (IMCR). These companies are all part of the "biological products, except diagnostic" industry.
Twist Bioscience (NASDAQ:TWST) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations.
Denali Therapeutics received 350 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 67.43% of users gave Denali Therapeutics an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
In the previous week, Denali Therapeutics had 23 more articles in the media than Twist Bioscience. MarketBeat recorded 42 mentions for Denali Therapeutics and 19 mentions for Twist Bioscience. Denali Therapeutics' average media sentiment score of 0.30 beat Twist Bioscience's score of 0.13 indicating that Denali Therapeutics is being referred to more favorably in the news media.
Denali Therapeutics has higher revenue and earnings than Twist Bioscience. Denali Therapeutics is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
Twist Bioscience presently has a consensus target price of $42.50, suggesting a potential upside of 0.31%. Denali Therapeutics has a consensus target price of $40.22, suggesting a potential upside of 119.67%. Given Denali Therapeutics' higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Twist Bioscience.
92.9% of Denali Therapeutics shares are held by institutional investors. 3.9% of Twist Bioscience shares are held by company insiders. Comparatively, 7.9% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Denali Therapeutics has a net margin of -36.51% compared to Twist Bioscience's net margin of -69.24%. Denali Therapeutics' return on equity of -11.46% beat Twist Bioscience's return on equity.
Twist Bioscience has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.
Summary
Denali Therapeutics beats Twist Bioscience on 14 of the 18 factors compared between the two stocks.
Get Twist Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Twist Bioscience Competitors List
Related Companies and Tools
